SomaLogic (NASDAQ:SLGC – Get Rating) is one of 42 public companies in the "Commercial physical research" industry, but how does it weigh in compared to its rivals? We will compare SomaLogic to similar businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Profitability

This table compares SomaLogic and its rivals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares SomaLogic and its rivals gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for SomaLogic and its rivals, as reported by MarketBeat.

SomaLogic currently has a consensus price target of $12.20, indicating a potential upside of 257.77%. As a group, "Commercial physical research" companies have a potential upside of 46.18%. Given SomaLogic's stronger consensus rating and higher probable upside, equities research analysts clearly believe SomaLogic is more favorable than its rivals.

Risk & Volatility

SomaLogic has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, SomaLogic's rivals have a beta of 5.23, suggesting that their average share price is 423% more volatile than the S&P 500.

Institutional & Insider Ownership

59.3% of SomaLogic shares are owned by institutional investors. Comparatively, 58.4% of shares of all "Commercial physical research" companies are owned by institutional investors. 12.9% of SomaLogic shares are owned by insiders. Comparatively, 11.9% of shares of all "Commercial physical research" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

SomaLogic beats its rivals on 7 of the 13 factors compared.

About SomaLogic

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.